The journal Annals of the Rheumatic Diseases (the highest impact journal in rheumatology worldwide with an impact factor of 9.270) has just published in its online edition the results from MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa), a large multicenter clinical trial led by Bioiberica, confirming the efficacy and safety of Droglican® for the treatment of osteoarthritis in patients with severe pain.
The Multicentric Osteoarthritis interVEntion Study with Sysadoa
(MOVES) was designed as an international multicentric, phase IV, double-blind, non-inferiority, randomized trial
to compare the efficacy and safety of a fixed dose combination of glucosamine hydrochloride + CS b-Biocative® versus celecoxib in patients with symptomatic knee OA with moderate to severe pain.
606 participants were included from 42 medical centers in France, Germany, Poland and Spain, being one of the largest studies recently carried out in osteoarthritis. Eligible patients were aged 40 and above, had knee OA grade 2 or 3 radiographic severity and had a WOMAC pain scale of >301 units (0-500 scale). Patients with high gastrointestinal or cardiovascular risk were excluded, according to the contraindications associated to celecoxib. The primary outcome was the mean decrease in WOMAC Pain subscale after 6 months of treatment.
Both drugs reduced the WOMAC Pain subscale by 50% without significant difference between groups at the end of the study. Further, there was no difference in all secondary outcomes assessing patient’s pain, functional capacity, stiffness, inflammation, joint swelling, effusion, and overall quality of life.
Overall, there was similar rescue medication consumption in both arms, and no significant difference was found in the proportion of adverse events, that were mild and evenly distributed among treatment groups.
These results confirmed those from the NIH-sponsored trial published in the New England Journal of Medicine in 2006 (Clegg et al 2006), which suggested that the combination of glucosamine hydrochloride and chondroitin sulfate yielded significantly better results than placebo in severe pain patients. Moreover, the combination CS b-Bioactive® + Glucosamine has shown a comparable efficacy to Celecoxib, with a better safety profile, which is of critical importance in a chronic disease such as osteoarthritis, often concomitant to other comorbidities.
The MOVES study adds to the growing body of clinical evidence that makes CS b-Bioactive® the most researched brand of chondroitin.
M. Hochberg, J. Martel-Pelletier, J. Monfort, I. Möller, J. R. Castillo, N. Arden, F. Berenbaum7, P. Conaghan, T. Pap, P. Richette, A. Sawitzke, P. du Souich, J. P. Pelletier, On behalf of MOVES Investigation Group. Multicentric osteoarthritis intervention study with SYSADOA (MOVES): Effects of combined glucosamine hydrochloride and chondroitin sulfate vs celecoxib for painful knee osteoarthritis. Ann Rheum Dis 2014;73(Suppl2)